Results 241 to 250 of about 885,766 (304)
We investigated cardiometabolic outcomes in patients treated with dapagliflozin 10 mg once daily or placebo after acute myocardial infarction according to LVEF at randomisation in the registry‐based, randomised DAPA‐MI trial. Regardless of baseline LVEF, dapagliflozin resulted in significant cardiometabolic benefits versus placebo, suggesting that ...
David Erlinge +19 more
wiley +1 more source
Kambo Administration and Its Association With Sudden Death: Clinical and Forensic Perspectives From a Systematic Review. [PDF]
Sacco MA +5 more
europepmc +1 more source
In a prospective, randomized study of high‐risk HF patients, simultaneous vaccination against influenza and RSV reduced the risk of the primary composite endpoint (hospitalization for HF, all‐cause death, or infection). The main driver of benefit was a lower incidence of infections.
Jan Biegus +14 more
wiley +1 more source
Salty Battle to Sudden Death: Young vs. Old, Brain vs. Heart. [PDF]
Iyer SH, Simeone KA.
europepmc +1 more source
Aims The prognostic significance of detecting left ventricular (LV) systolic dysfunction during family screening programmes (FSPs) in relatives of probands affected by dilated (DCM) and non‐dilated left ventricular (NDLVC) cardiomyopathies remain unclear.
Eva Del Mestre +17 more
wiley +1 more source
An integrated approach including late gadolinium enhancement data and genetics to predict left ventricular reverse remodelling in patients with dilated and non‐dilated left ventricular cardiomyopathy. DSP, desmoplakin; FLNC, filamin C; LMNA, lamin A/C; LVRR, left ventricular reverse remodelling; LGE, late gadolinium enhancement; MVA, major ventricular ...
Martina Setti +21 more
wiley +1 more source
Alterations in ECG and Right Heart Catheterization Data in PAH Patients Who Died From Sudden Death Compared With Right Heart Failure. [PDF]
Flemington AB +3 more
europepmc +1 more source

